Close

Anti-C9H7N5O3 T cell receptor (M33.64), pCDTCR1 (TCR-YC0300)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The M33.64 cell line was activated in response to 5-OP-RU and E. coli but also exhibited robust, MR1-dependent activation in the absence of added Ag, consistent with it being stained with empty MR1 tetramer. The MAV36 TCR+ cells were activated when co-cultured with C1R.MR1 cells in the presence of E. coli or 5-OP-RU, but showed little response without added Ag. To further investigate the M33.64 TCR autoreactivity, the M33.64 TCR+ cell line was co-cultured with MR1-transduced C1R cells that were flow cytometrically sorted based on graded MR1 expression. The M33.64 TCR+ cells upregulated CD69 in an MR1-dose-dependent manner, without added Ag, confirming that in contrast to other MAIT TCRs, the M33.64 TCR is MR1 autoreactive.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • C9H7N5O3
  • Epitope
  • N(2)-acetyl-6-formylpterin
  • Format
  • Non-Modified TCR
  • Allele
  • human MR1
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • M33.64
  • Host Species
  • Human

Target

  • Introduction
  • Pterin acetylated on N-2 and carrying a formyl group at position 6.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-C9H7N5O3 T cell receptor (M33.64), pCDTCR1 (TCR-YC0300). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.